Literature DB >> 28144253

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Maciej Banach1, Piotr Jankowski2, Jacek Jóźwiak3, Barbara Cybulska4, Adam Windak5, Tomasz Guzik6, Artur Mamcarz7, Marlena Broncel8, Tomasz Tomasik5, Jacek Rysz9, Agnieszka Jankowska-Zduńczyk10, Piotr Hoffman11, Agnieszka Mastalerz-Migas12.   

Abstract

Entities:  

Year:  2016        PMID： 28144253      PMCID： PMC5206369          DOI： 10.5114/aoms.2017.64712

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN： 1734-1922            Impact factor:   3.318


× No keyword cloud information.
  153 in total

Review 1.  Ezetimibe.

Authors:  Harold Bays
Journal:  Expert Opin Investig Drugs       Date:  2002-11       Impact factor: 6.206

2.  Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.

Authors:  D Hunt; P Young; J Simes; W Hague; S Mann; D Owensby; G Lane; A Tonkin
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

3.  Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Authors:  H E Bays; P B Moore; M A Drehobl; S Rosenblatt; P D Toth; C A Dujovne; R H Knopp; L J Lipka; A P Lebeaut; B Yang; L E Mellars; C Cuffie-Jackson; E P Veltri
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

4.  [Prevalence of main risk factors for ischemic heart disease in a cohort of 41,972 participants from Southern Poland Epidemiological Survey].

Authors:  M Tendera; K Kozakiewicz; M Bartnik; E Małecka-Tendera
Journal:  Wiad Lek       Date:  2001

5.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Authors:  Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

6.  Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.

Authors:  Carlos A Dujovne; Mark P Ettinger; J Frederick McNeer; Leslie J Lipka; Alexandre P LeBeaut; Ramachandran Suresh; Bo Yang; Enrico P Veltri
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

7.  Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

Authors:  R H Knopp; H Gitter; T Truitt; H Bays; C V Manion; L J Lipka; A P LeBeaut; R Suresh; B Yang; E P Veltri
Journal:  Eur Heart J       Date:  2003-04       Impact factor: 29.983

8.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

9.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Authors:  Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

10.  Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus.

Authors:  Christine M Thorburn; Michael M Ward
Journal:  Arthritis Rheum       Date:  2003-09
View more
  27 in total

1.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Gani Bajraktari; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; Demosthenes B Panagiotakos; Gyorgy Paragh; Dimitri P Mikhailidis; Olena Mitchenko; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Kausik K Ray; Manfredi Rizzo; Amirhossein Sahebkar; Maria-Corina Serban; Laurence S Sperling; Peter P Toth; Dragos Vinereanu; Michal Vrablík; Nathan D Wong; Maciej Banach
Journal:  Arch Med Sci       Date:  2017-08-04       Impact factor: 3.318

2.  Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey.

Authors:  Piotr Jankowski; Dariusz A Kosior; Paweł Sowa; Karolina Szóstak-Janiak; Paweł Kozieł; Agnieszka Krzykwa; Emilia Sawicka; Maciej Haberka; Małgorzata Setny; Karol Kamiński; Zbigniew Gąsior; Aldona Kubica; Dirk De Bacquer; Guy De Backer; Kornelia Kotseva; David Wood; Andrzej Pająk; Danuta Czarnecka
Journal:  Cardiol J       Date:  2020-05-21       Impact factor: 2.737

3.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

4.  Cardiovascular risk and metabolic profile of Polish citizens from Lower Silesia. First signs of metabolic crisis?

Authors:  Lukasz Kozera; Wiktor Kuliczkowski; Elzbieta Gocek
Journal:  Arch Med Sci       Date:  2020-10-14       Impact factor: 3.707

5.  Prevalence of dyslipidemia and associated risk factors among adult residents of Shenmu City, China.

Authors:  Huiping Gao; Haiying Wang; Guangliang Shan; Rui Liu; Haiyuan Chen; Shengli Sun; Yonglin Liu
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

6.  Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol.

Authors:  Istvan Reiber; Laszlo Mark; Gyorgy Paragh; Peter P Toth
Journal:  Arch Med Sci       Date:  2020-08-03       Impact factor: 3.318

7.  Assessing Screening Guidelines for Cardiovascular Disease Risk Factors using Routinely Collected Data.

Authors:  Jaspreet Pannu; Sarah Poole; Neil Shah; Nigam H Shah
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

Review 8.  MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Authors:  Amir Abbas Momtazi; Maciej Banach; Matteo Pirro; Evan A Stein; Amirhossein Sahebkar
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 9.  Management of Statin Intolerance in 2018: Still More Questions Than Answers.

Authors:  Peter P Toth; Angelo Maria Patti; Rosaria Vincenza Giglio; Dragana Nikolic; Giuseppa Castellino; Manfredi Rizzo; Maciej Banach
Journal:  Am J Cardiovasc Drugs       Date:  2018-06       Impact factor: 3.571

10.  Hypercholesterolaemia - practical information for non-specialists.

Authors:  Handrean Soran; Safwaan Adam; Jamal B Mohammad; Jan H Ho; Jonathan D Schofield; See Kwok; Tarza Siahmansur; Yifen Liu; Akheel A Syed; Shaishav S Dhage; Claudia Stefanutti; Rachelle Donn; Rayaz A Malik; Maciej Banach; Paul N Durrington
Journal:  Arch Med Sci       Date:  2017-12-19       Impact factor: 3.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.